Ch ief Au t h or a n d Ed it or : An d r ew Pen gelly Ph D, AHG, FNHAA Assist a n t Au t h or : Ka t h leen Ben n et t Ed it or ia l Tea m: Ja mes Sn ow AHG Bevin Cla r e MS, AHG Nor a Ziet z Deb or a h Mizu r Lin d sa y Klu ge Mimi Her n a n d ez, MS, RH ( AHG)
Citation Instruction: Pengelly, A., & Bennett, K.,(2011). Appalachian plant monographs: Panax quinquefolius L., American ginseng. Retrieved from http://www.frostburg.edu/aces/appalachian- plants/
2
American Ginseng Panax quinquefolius L. 1. Taxonomy Panax quinquefolius L. Family: Araliaceae Common names: American ginseng, five finger root, sang, tartar root, redberry, mans health, root of life, dwarf groundnut, garantogen, jinshard, ninsin, little man, garent-oquen. Synonyms: Panax quinquefolium (L.) Alph.Wood, Aralia quinquefolia (L.)Decne. & Planch., Ginseng quinquefolium (L.) Alph.Wood, Panax americanus (Raf.) Raf., Panax cuneatus Raf..
Two species of Panax (P. quinquefolius and P. trifolius L.) are native to North America. The latter species is much smaller and rarely used for medicinal purposes. There are 11 species globally, several of which are Asian, most notably P. ginseng C.A.Mey. known as Korean or Asian ginseng.
2. Botany and distribution P. quinquefolius is a slender deciduous perennial growing to a height of 2 feet and bearing palmate-compound, serrated leaves at the apex of the stem. Individual leaflets range from lance Figure 1. Image from Applied and Economic Botany by Henry Kraemer. Published by author, 1914.
3
shape to oblong. Leaves from young plants may consist of only three leaflets. As the plant matures, more sets of these leaves appear, but it is rare to see plants with four or more compound leaves or prongs as they are known. As the stem (sympodium) dies back each fall it leaves a bud scar on the root collar or rhizome - these are used as a means of assessing the plants age (Rural Action Inc., 2005). Adventitious roots may form from these nodes in older plants (Van Der Voort, Bailey, Samuel, & McGraw, 2003).
Small whitish flowers appear in the summer, born on a simple umbel in the main leaf axis. These are followed by red berry-like fruit containing up to three seeds. Seeds remain dormant for well over a year, germinating in the second spring season (Schlag & McIntosh, 2004). P. quinquefolius also has the ability to remain in a dormant state for a year or several years when weather conditions are adverse (Taylor, 2006).
Ginseng roots are fleshy white or light colored tap roots, and variably branched. As the plant ages it sometimes puts out an auxiliary root that may act as a spare if the main root is damaged (Elliot, 1976)
The preferred habitat for P. quinquefolius is in the shady understory of deciduous hardwood forests in Eastern USA and Canada. It was once quite prevalent in the Appalachian region though now its distribution is quite patchy (Case, Flinn, Jancaitis, Alley, & Paxton, 2007; McGraw, Sanders, & Voort, 2003) and gene flow between populations is restricted (Assinewe, Baum, Gagnon, & Arnason, 2003; Cruse-Sanders & Hamrick, 2004). It likes well-drained, humus-rich soil and prefers east-facing slopes (Foster & Johnson, 2006). Parts Used The dried root, harvested from plants at least 6 years old, in late summer and fall. Research indicates the leaves and fruit are also pharmacologically active. 3. Traditional Uses Traditional use in Appalachia P. quinquefolius has traditionally been administered as a tea for general tonic purposes and as an aphrodisiac. It is used to dispel a cough and promote perspiration in colds, driving out the force of illness from within (Crellin & Philpott, 1990). It is cultivated and revered in central and eastern North America by tribal and Appalachian cultures for its longevity-promoting effects, although differentiation between Chinese and American ginseng uses has often been blurred (Duke, 1986; Millspaugh, 1974). P. quinquefolius has also been used as a poultice for boils and decoctions of the roots have been taken to relieve headaches and female troubles (Banks, 2004). It is said that the root of P. quinquefolius ceased unpleasant dreams in children and infants and remedied issues relating to flatulence and colic (Howell, 2006).
P. quinquefolius has been traded interstate and overseas for hundreds of years, and it remains an integral part of the Appalachian economy (Cavender, 2003). Traditional use - general European interest in P. quinquefolius can be dated back to the early 18 th century when a French Jesuit, Joseph-Francois Lafitau, spent many years amongst the Canadian Mohawk Nation
4
searching for an American equivalent to Asian ginseng. His quest was so successful that a ginseng industry was quickly established, and within a few years large quantities were being exported to China (Taylor, 2006). Native American Before Lafitaus discovery of the similarity between Asian and American ginseng, P. quinquefolius was already a medicinal agent in native traditions (Taylor, 2006). The Iroquois Indians used ginseng for a variety of disorders including upset stomach, sore eyes and tape worm, but also as an article to give thanks and for preventative health care (Taylor, 2006). Other recorded Native American uses of this herb included applications as an analgesic, anticonvulsive, expectorant, digestive tonic, gynecological aid, & general tonic (Moerman, 1998). It was sometimes used as a remedy for headaches and colic. Folklore & Home The main home use of American ginseng was as a digestive stimulant particularly for the weakened or uneasy stomach. It was also used to treat a sluggish nervous system and strengthen the circulation (Harding, 1936). Physiomedical P. quinquefolius was said to have sedating and relaxing effects, and was used to address dyspepsia as well as nervous sensitiveness with debility (Cook, 1869). Its main action was a nervine tonic and relaxant to the whole body, with a particular affinity for the brain. Eclectic Felter (1922) and Scudder (1870) report that the root of P. quinquefolius required long-term use to be effective. It was used as a nervous system sedative, having the greatest effects on calming nervous dyspepsia as well as mental and other forms of nervous exhaustion from overwork. Felter noted its use as a long term, building tonic for patients with depleted resources, particularly cerebral anemia (Felter, 1898). Regulars Allopathic physicians found little use for P. quinquefolius except as a demulcent and as a flavorful root to chew (Remington & Wood, 1918). Many believed that ginsengs medicinal qualities were a myth of the Chinese and had little use for it in this country as an effective medicine (Wood & Bache, 1858). Nevertheless P. quinquefolius was official in the United States Pharmacopoeia (USP) from 1842 until 1882 (Blumenthal, 2003). China P. quinquefolius is used in Traditional Chinese Medicine to treat deficiency conditions associated with symptoms such as fatigue, irritability, thirst and dryness of the mouth or respiratory tract (Chen & Chen, 2004) 4. Scientific Research Phytochemistry The most significant group of active constituents in P quinquefolius and P. ginseng are a group of triterpenoid saponins known as ginsenosides. Ginsenosides are glycosides whose aglycones have dammarane-type structures. A rare ocotillo-type saponin known as 24-R-
5
pseudoginsenoside is found only in P. quinquefolius (Leung & Wong, 2010). Another class of dammarane-type triperpene oligoglycosides (quinquenosides I-V) are also found in the species (Yoshikawa et al., 1998).
A wide range of extraction, separation and detection methods have been applied for the determination of ginsenoside structures and levels in different plant sections. These methods include high-performance liquid chromatography (HPLC), mass spectroscopy (MS), diode-array detectors (DAD), infra-red (IR) spectroscopy and evaporative light scattering detection (ELSD) (Ferreira, Ebbs, Murphy, & Corbit, 2005; Jia, Zhao, & Liang, 2009; Orsat & Dai, 2010; Qi, Wang, & Yuan, 2011; Wan, Li, Chen, & Wang, 2007; Yat et al., 1998). The United States Monograph (USP, 2004) includes TLC and HPLC methods for ginsenoside evaluation, with the acceptable total content being no less than 4% of the dried roots (USP, 2004). Modifications to the USP methods have been recommended, in an attempt to overcome inconsistent results observed from the use of different HPLC columns (Li, Chen, Chou, Want, & Hu, 2004). For identity of pseudoginsenoside F11, HPLC was coupled with ELSD (Li & Fitzloff, 2001).
Using ultra-performance LC linked with MS for separation and identification, G. Xie et al (2008) further analyzed five ginseng species by principal component analysis and found that P. quinquefolius was readily discriminated from the other four species tested. Gene sequencing experiments have also led to an understanding of the biosynthesis of ginsenosides; the genes encoding enzymes identified include 150 cytochrome P450 and 235 glycosyltransferase sequences unique to P. quinquefolius (Sun et al., 2010).
Ginsenosides are classified into two main groups known as protopanaxadiol (PPD) and protopanaxatriol (PPT), based on the hydroxylation pattern at C6 and attachment of sugar moieties (Table 1). Phytochemically Panax species are distinguished by the ratio between these groups (Hall, Lu, Yat, Fitzloff, et al. 2001). For example P. ginseng ginsenosides are mainly of the PPD group, while PPTs are more prominent in P. quinquefolius although Rf is entirely absent. Further differentiation may be made by the ratios of Rg1/Rb1 and Rb2/Rb1 which tend to be higher in P. ginseng (Yuan, Wang, Wicks, & Qi, 2010) although some wild populations of P. quinquefolius have been found to have high Rg1/Rb1 ratios (Schlag & McIntosh, 2006). As a generalization the most prominent P. quinquefolius constituents are Rb1 and Re (Assinewe et al., 2003). However North America P. quinquefolius populations have been further differentiated according to their Rg1/Re ratio (Schlag & McIntosh, 2006; McIntyre et al. 2011). The variation in chemotypes is not only significant for identification purposes - they also have clinical implications as discussed below under metabolism. The main ginsenosides in P. quinquefolius are listed in Table 2.
6
Table 1. Classification of ginsenosides in Panax spp. (Leung & Wong, 2010). Compounds are named according to a decreasing polarity scale (i.e.water solubility). Generally the PPT group is more polar due to the extra hydroxyl group e.g. Re, while the less polar PPDs tend to be lower in the alphabet eg. Rb. Protopanaxadiol group (PPD) Protopanaxatriol group (PPT) Others Rb1, Rb2, Rb3 Re F11 ocotillo saponin (P. quinquefolius only) Rc Rf (P. ginseng only) Oleanane saponins Rd Rg1, Rg2 Quinquenosides Rg3 Rh1 Rh2 Rs1
Table 2: Main ginsenosides and ratios typical of P. quinquefolius Ginsenosides and their ratios Rb1 Rg1 Rg1 / Rb1 < 1 (see text for clarification) Re F11 ocotillo saponin - 24R-pseudoginsenoside Rf / F11 ratio =0.1
Ginsenoside content will also vary as a consequence of increased temperatures. P. quinquefolius grown at high temperatures tends to accumulate less biomass and develop smaller roots, leading to a reduction in total ginsenoside content (though not concentration) in plants subjected to a 5C increase in growth temperatures in comparison to controls (Jochum, Mudge, & Thomas, 2007). Preferential selection of larger roots for analysis of ginsenosides and polyacetylenes did not influence the concentrations of either group of constituents (Christensen & Jensen, 2008).
7
Ginsenoside levels are not influenced by root shape or section harvested, although root fibre has higher concentrations - though not of Rb1 (Roy, Grohs, & Reeleder, 2003). Other factors that may act as predictors of ginsenoside concentration are age and stage of plant development, soil pH, light concentration (Schlag, 2004) and understory light levels including the effect of sun flecks (Fourniera et al, 2003), while variation may also be found between cultivated, wild and wild-simulated plant material this in turn is influenced by the seed source (Schlag, 2004). Exposure of the roots to soil-borne heavy metals such as lead and arsenic can also influence ginsenoside production in ginseng roots (Corbit, Ebbs, King, & Murphy, 2006).
In a surprise finding, J.-T. Xie et al (2004) revealed that for Wisconsin cultivated P. quinquefolius the leaves contain far higher levels of ginsenosides (15.3%) compared to the berries (10.8%) and root (5.5%), and the ratio of the leaf components also differed, with particularly high concentrations of Rd and Re. By contrast Assinewe et al (2003) found the leaves of seven wild populations to contain only 3.33% ginsenosides compared with 5.78% for root.
Huge variability exists between different ginseng commercial products, partly due the number of species marketed as ginseng, as well as differences within products from the same species (Harkey, Henderson, Gershwin, Stern, & Hackman, 2001). In an attempt to identify mislabeled and adulterated products marketed as ginseng in North America, and to develop a set of standardized tests for identity and quality, the American Botanical Council initiated the Ginseng Evaluation Program in collaboration with the Universities of Ottawa and Chicago (Hall, Lu, Fitzloff, Arnason, Awang, Fong, & Blumenthal, 2001). Pharmacokinetics There have been few pharmacokinetic investigations into P. quinquefolius. Those available are based around the ginsenosides, which are found to be of low bioavailability (Jia et al., 2009; Reeds et al., 2011). This is partly a result of the first-pass metabolism that occurs, leading to formation of metabolites which may in fact be more potent that the ginsenoside pro-drugs from which they derive (Bae et al., 2004).
Ginseng saponins appear to be readily degraded under mild acid conditions such as found in the human stomach. For example ginsenosides Rg1, Re and Rb1 were shown to yield their prosapogenins under such conditions (Han et al., 1982). In further studies Bae, Han, Choo, Park, and Kim (2002) demonstrated the formation of ginsenoside Rg3 following mild acid treatment. This Rg3 metabolite was further transformed by human intestinal bacteria to Rh2, which showed increased cytotoxicity against tumor cells and Heliobacter pylori in vitro. Ginsenoside Rb1 occurs in both an acid form (malonyl-Rb1) and the neutral form, which in cultivated P. quinquefolius are in approximately equal proportions (Awang, 2000). The acidic form can be converted to neutral Rb1 by steaming or by digestion in the stomach, after which it is further converted by anerobic bacterial enzymes to a more polar and more active metabolite - Rd ( Kim, Lee, & Lee, 2005). Removal of glucose units from Rd by intestinal bacteria leads to formation of Intestinal Bacterial Metabolite (IBM) also called compound K this unit can be absorbed into the bloodstream (Awang, 2000). Ginsenosides Rb2, Rc and Rd follow a similar route.
Ginseng metabolites have also been shown to have more significant cytochrome P450 influence compared to the natural saponins (Liu et al., 2006). These studies provide further evidence that
8
ginsenosides actually act as pro-drugs, which depend on transformation by stomach acid and intestinal bacteria to release their active constituents (Bae, Han, Kim, & Kim, 2004). For a flow chart that displays the stages of biotransformation of the various ginsenosides by intestinal microflora to their metabolites, see Leung & Wong (2010).
In addition to first pass effect, ginsenoside profiles may also be influenced by steaming ginseng a common tradition in Asia. HPLC profile comparisons between steamed and unsteamed P. quinquefolius roots have been published (Qi, Wang, & Yuan, 2010). When berries were steamed in a separate study, the overall level of ginsenosides was reduced however there was significant augmentation of Rg3, a recognized anticancer agent (Wang et al., 2006). Rg3 has also been identified in heat-processed P. ginseng (Bae, et al. 2002). Polyacetylenes Polyacetylenes are small lipid soluble molecules of limited distribution in plants. The major such compounds in P. quinquefolius roots are the alcohols falcarinol and panaxydol (Christensen, Jensen, & Kidmose, 2006), while others include PQ-1 PQ-8 (all previously unknown), panaxytriol, acetylpanaxydol and ginsenoyne G (Fujimoto, Satoh, Takeuchi, & Kirisawa, 1991; Fujimoto, Wang, Kirisawa, Satoh, & Takeuchi, 1992; Fujimoto, Wang, Satoh, & Takeuchi, 1994; Satoh et al., 2007) and a recently discovered compound 3-oxy-PQ-1 (Satoh et al., 2007). The main analytical methods for identification and quantification of polyacetylenes in P. quinquefolius roots are HPLC, MS and C/H-NMR, while Christensen et al. (2006) have developed an HPLC method for simultaneous analysis of ginsenosides and polyacetylenes. Polysaccharides Numerous polysaccharides as well as oligosaccharides and monosaccharides have been extracted from P. quinquefolius. Assinewe, Amason, Aubry, Mullin, & Lemaire (2002) extracted a linear polysaccharide fraction which, upon acid hydrolysis, was found to yield mainly glucose with small amounts of galactose and arabinose and a 9% uronic residue. A commercial extract standardized to polysaccharide content has been developed by CT Technologies. CVT-E002 (COLD-fx
) is comprised of poly-furanosyl-pyranosyl-saccharides that have been shown to
stimulate the immune system (Shan, Rodgers, Lai, & Sutherland, 2007). Other constituents Apart from saponins P. quinquefolius contains phenolic compounds, amino acids, flavonoids, volatile oils, vitamins and minerals (Schlag, 2004; Jia et al, 2009; Qi, Wang, & Yuan, 2011). Pharmacology Pharmacology of ginsenosides As mentioned above, individual ginsenosides provide significantly different pharmacological effects, hence the interest in ascertaining specific levels and ratios. This is exemplified by the two major ginsenosides Rb1 and Rg1 characteristic of P. quinquefolius and P. ginseng respectively. Rb1 tends to be more of a depressant (more yin, eg inhibiting angiogenesis) while Rg1 is a mild stimulant (more yang, eg. promoting angiogenesis) (Harkey et al., 2001; Sengupta et al., 2004). Further correlations between individual ginsenosides and their activities are listed in Table 3.
9
Table 3. Some pharmacological effects of ginsenosides Compound Pharmacological action Reference Rb1 Estrogen-like activity Anti-diabetic, insulin sensitizing Antiobesity Angiogenesis inhibitor Neurotropic, neuroprotective Benishin, Lee, Wang, & Liu, 1991; Duda et al., 1996; Papapetropoulos, 2007; Radad et al., 2004; Rudakewich, Ba, & Benishin, 2001; Sengupta et al., 2004; Shang et al., 2007; Shang et al. 2008; Xiong et al., 2010 Rc Inhibit proliferation of breast cancer cells Murphy, 2002 Re Anti-diabetic Antioxidant, cardioprotective Attele et al., 2002; Yuan et al., 2010 Rg1 Neurotropic, neuroprotective Ligand for glucocorticoid receptor Suppresses oxidative stress Promotes angiogenesis Chen, Chen, Zhu, Fang, & Chen, 2002; Chen et al., 2003; Lee et al., 1997; Radad et al., 2004; Rudakewich et al., 2001; Radad et al., 2004; Sengupta et al., 2004 Rg2 Neuronal Ach inhibitor Sala et al., 2002 Rg3 Inhibits proliferation of prostate cancer cells H-S Kim et al., 2004 Rh1 Activates estrogen receptor Lee et al., 2003 Rh2 Cytotoxic, inhibits breast cancer cell proliferation Inhibits proliferation of prostate cancer cells H-S Kim et al. 2004; Murphy, 2002 F11 Assists memory improvement Neuroprotective Z. Li, Guo, Wu, Li, & Wang, 1999; Wu et al., 2003
Effects on blood sugar and metabolism Numerous studies indicate that P. quinquefolius reduces postprandial glycemia in diabetic and non-diabetic human subjects in doses as low as 1g, suggesting a possible role for this species in complementing existing diabetic treatment (Vuksan et al., 2000a; Vuksan et al, 2000b; Vuksan et
1 0
al, 2001). However, in one case when a different batch of P. quinquefolius from the same supplier - but with a much lower ginsenoside profile - was tested, no such effect was observed (Sievenpiper, Arnason, Leiter, & Vuksan, 2003). In a separate study using P. ginseng no hypoglycemic effects were shown, rather there was a tendency towards elevated glucose (Sievenpiper et al., 2003). This finding was confirmed in a subsequent study of several species and types of ginseng in which the ginsenoside ratio (PPD:PPT) is posited as a significant factor in the variable glycemic response (Sievenpiper, Arnason, Leiter, & Vuksan, 2004). Yet in a recent study using five batches of Ontario-grown P. quinquefolius reduced postprandial glycemia and insulinemia were shown for three of the batches but not for the other two, and variations in ginsenoside content did not correlate with these differences (Dascalu et al, 2007). Studies in animals using P. quinquefolius leaves with high ginsenoside levels (referred to above) also demonstrated marked anti-hyperglycemic activity (J.-T. Xie et al., 2004), and similar results have been obtained using berry extracts of both P. quinquefolius and P. ginseng (Attele et al., 2002; J-T Xie, Mehendale, & Yuan, 2005). In a recent in vivo antidiabetic screening study of ninety botanical species, all three P. quinquefolius products (rhizome, leaf, berry) tested positive for lipogenic activity, however P. ginseng did not (Babish et al, 2010). Lipogenesis improves insulin sensitivity as new adipocytes take up more glucose and secrete fewer detrimental cytokines compared to the larger adipocytes they replace (Babish et al., 2010). Ginsenoside E has been identified as a specific hypoglycemic agent (Attele et al., 2002) although to date studies in humans do not support this effect (Reeds et al., 2011).
Ginsenoside Rb1 also suppressed food intake and body weight gain in obese rats, while improving glucose homeostasis. Modulation of associated signaling pathways and neuropeptides in the hypothalamus was observed (Xiong et al., 2010). Further studies with mice treated with polysaccharides extracted from the fruit suggest the polysaccharides are another potential component associated with anti-hyperglycemic activity for P. quinquefolius (Xie et al. 2004).
Molecular studies based on P. ginseng indicate ginsenosides suppress gene expression associated with the nuclear hormone receptors peroxisome proliferator-activated receptors (PPAR) in vitro and in vivo (Yoon et al., 2003; Banz et al., 2007). Furthermore, a specific ginsenoside Rb1 has been found to activate PPAR - a transcription factor in adipogenesis - and increase expression of glucose transporters (GLUT) 1 and 4 in vitro. PPAR regulation has been linked to improved insulin sensitivity and reductions of lipid accumulation in muscle and liver (Banz et al., 2007) PPARs are also molecular targets for the anti-diabetic drugs known as TZDs (Kyu et al., 2006).
In sum these studies confirm a marked benefit on glycemic profiles at low doses for P. quinquefolius but the benefits for P. ginseng species are less consistent. While differences in ginsenoside levels and their ratios may influence the efficacy of P. quinquefolius it would appear that other components may also be involved (Sievenpiper et al., 2004).
Diabetic renal damage Animal studies suggest that heat-processed P. quinquefolius (H-AG) extracts may have beneficial effects on renal damage associated with diabetic nephropathy. H-AG significantly decreased elevated urinary protein levels in streptozotocin (STZ)-induced diabetic rats, increased creatinine clearance and significantly reduced accumulation of advanced
1 1
glycation endproducts (AGE) - a weaker effect on AGE was found with the unprocessed P. quinquefolius extract (H. Y. Kim, Kang, Yamabe, Nagai, & Yokozawa, 2007). Cardiovascular effects Preliminary studies on rats have demonstrated potential cardioprotective, anti-ischemic, antioxidant, calcium channel blocking and platelet aggregate moderating effects of P. quinquefolius (Yuan et al., 2010). Four months of dietary supplementation decreased oxidation damage to heart and muscle fibres with P. quinquefolius powder in rats (Fu & Ji, 2003). Promotion of angiogenesis to infarcted or ischemic regions by an extract high in saponins was shown to provide cardioprotection in vivo (Wang, Shi, & Yin, 2007). Ginseng species have ambiguous effects on angiogenesis promoting wound healing on the one hand (dependent on angiogenesis) and inhibiting tumor growth via an antiangiogenic action on the other (Sengupta et al., 2004). These contrasting properties have been linked to specific ginsenosides (Rb1 as inhibitor and Rg1 as inducer of angiogenesis respectively). Rb1 angiogenesis inhibition has been linked to agonistic effect on estrogen receptor (Papapetropoulos, 2007). Memory and cognition In contrast to the mild central nervous system (CNS) stimulant effects of P. ginseng, P. quinquefolius has a calming influence on the CNS (Yuan et al., 2010). There is a great deal of evidence demonstrating that ginseng species in general and specific ginsenosides have multiple effects in the CNS, an affinity for a wide range of receptors in the CNS (Yuan et al., 2010) and specific influence on hippocampal neurons (Rausch, Liu, Gille, & Radad, 2006; Jia et al., 2009) . Animal studies show cognitive enhancing and neuroprotective actions for P. quinquefolius, and specifically for ginsenosides Rb1 and Rg1 though possibly via different mechanisms (Benishin et al., 1991; Rudakewich et al., 2001). Rb1 facilitated release of acetylcholine from the hippocampus and increased choline in nerve endings (Benishin et al., 1991). Rb1, and to a less extent Rg1, extended the survival time of dopaminergic neurons against a selective neurotoxin (Radad et al., 2004). There is a particular focus on the use of ginseng products for prevention and treatment of degenerative brain disorders such as Parkinsons and Alzheimers diseases (Jia et al., 2009; Radad et al., 2006; Rausch et al., 2006).
Common cold and immunity Polysaccharide-rich extracts have been found to increase proliferation of spleen cells and macrophage activity in cell cultures as well as stimulate immunoglobulin G (IgG) in vivo and tumor necrosis factor (TNF) production from macrophages (Assinewe et al, 2002; Wang et al., 2001). Increased TNF- production also occurred in blood samples of three human volunteers following intake of P. quinquefolius (Zhou & Kitts 2002). CVT-E002 a water soluble extract standardized for polysaccharides, is marketed under the patented name COLD-fX for the treatment of upper respiratory tract infections (Wang et al., 2004) and has been subjected to several clinical investigations (see Clinical Studies' section below).
Mechanisms of anti-inflammatory activity have also been studied. Treating murine macrophages with P. quinquefolius extract quantified to contain 10% ginsenosides, LPS-induced nitrous oxide (iNOS) expression was inhibited, apparently by suppression of signal transducer and activator of transcription (STAT) cascade (Ichikawa et al., 2009).
Cancer
1 2
There has been considerable interest in the potential use of ginseng in cancer for many decades. Initially this interest focused mainly on using P. ginseng as an adjuvant to enhance efficacy and reduce side-effects of active cancer therapies such as chemotherapy and radiotherapy based on the herb's reputation as an adaptogenic agent (Jia et al., 2009). During the last decade there have been numerous investigations into the potential for P. quinquefolius to assist in the prevention and treatment of various forms of cancer.
Qi et al (2010) have explored potential structure-function relationships of ginsenosides in P. quinquefolius, identifying a number of possible cancer-prevention mechanisms including cell cycle modification, induction of apoptosis, and inhibition of angiogenesis and pro-inflammatory pathways. For a comprehensive review of studies and mechanisms involving ginseng and cancer see Jia et al. (2009). Breast cancer Using the standardized extract CNT-2000, studies on ER positive breast cancer cells showed dose-dependent decreases in cell and paradoxically an ability to induce expression of the estrogen-related gene pS2. There was no interference with the estrogen antagonist drug Tamoxifen when used concurrently, suggesting the possibility for synergistic interactions with conventional breast cancer agents (Duda et al., 1999). In a subsequent study the CNT-2000 extract was found to be an inducer of the p21 protein, a universal cell cycle inhibitor, in estrogen sensitive and insensitive breast cancer cell lines, suggesting a molecular mechanism of action for inhibition of breast cancer (Duda, Kang, Archer, Meng, & Hodin, 2001). Rice and Murphy confirmed in vitro inhibition of breast cancer cells, and further identified potent inhibition by a combination of ginsenosides Rc and Rh2. The two compounds appear to act via different mechanisms, Rc inhibiting progression of the cell cycle and Rh2 showing cytotoxic activity (Murphy, 2002). Further in vitro studies have elicited other potential molecular mechanisms, including induction of apoptosis through activation of a protease, and via protein kinase signaling pathways in cancer cells (King & Murphy, 2007). Other cancers
Polyacetylenes in P. quinquefolius are cytotoxic to leukemia cells (Fujimoto et al., 1992). Ginsenosides Rg3 and Rh2 have been shown to inhibit DNA synthesis in prostate cancer cells, to induce cell detachment and to modulate protein kinases (H.-S. Kim et al., 2004). Rg3 can also inhibit metastasis of ovarian cancer cells in vitro (Xu et al., 2008). Miller, Delorme, and Shan (2009) conducted studies on mice with viral-induced tumors (erythroleukemia). Mice that were given 40mg/d of the CNT-2000 extract survived up to 50% longer compared to controls. When human colon cancer cells were exposed to P. quinquefolius extracts, cell proliferation and cell cycle progression was inhibited, an effect which was associated with both ginsenosides and polysaccharides (King, & Murphy, 2010).
Endocrine effects The effect of ginseng on human hormones has long been a source of controversy. Laboratory investigations indicate ginsenoside Rb1 is an estrogen receptor agonist (Papapetropoulos, 2007); Leung et al., 2006). P. quinquefolius extract has also been shown to activate estrogen receptors however the effect was shown to depend on the extraction solvent used aqueous extractions
1 3
(which are polysaccharide rich) provide no estrogenic activity (King, Adler, & Murphy , 2006). Rg1 activates glucocorticoid receptors (Lee et al., 1997) however this does not necessarily imply the ginsenoside acts like a steroid hormone (Leung & Wong, 2010). Clinical Trials Common cold McElhaney et al. (2004) found that when COLD-fx was taken early in the cold and flu season the relative risk and duration of the common cold in a group of 43 elderly subjects was reduced compared to placebo by 48% and 55% respectively. In a larger trial of 323 subjects aged 18-65 years, the mean number of colds in the ginseng group was significantly reduced compared to the placebo group; severity of symptoms was reduced and the duration was also reduced by 2.4 days these results are comparable to those of common antiviral drugs used for treatment of influenza (Predy et al., 2005).
Recently in a systemic review of five randomized clinical trials (four using COLD-fx, one Ginsana G-115- P. ginseng), the authors noted a consistent trend towards a lower risk of developing the common cold and evidence in two trials (both COLD-fx) that duration of colds and other acute respiratory infections was reduced by an average of six days. They concluded however that there is insufficient evidence to recommend ginseng extracts for prevention of the common cold (Seida, Durec, & Kuhle, 2009). Memory and cognition Recently an acute randomized double-blinded clinical study of 32 healthy young adults demonstrated significant improvement in working memory and other cognitive measures following ingestion of varying doses of P. quinquefolius extract (Cereboost TM ) standardized to 11.65% ginsenosides (Scholey et al., 2010). Cancer A randomized double-blind pilot study was conducted on 290 adult patients with a history of cancer-related fatigue, who were given ascending doses of 4-year old Wisconsin grown P. quinquefolius over eight weeks. The groups who received doses of 1,000 and 2000 mg daily appeared to have less fatigue compared to the group taking a placebo, as assessed by various validated scales (Barton et al., 2009). By contrast a randomized controlled crossover trial of ten healthy males given 1,125mg of CNT-2000 (a proprietary extract also known as North American Ginseng Extract (NAGE) containing 10% ginsenosides daily for five weeks failed to show significant effects on immune response as assessed by changes to white blood cell levels, lymphocyte proliferation or neutrophil oxidative burst (Biondo et al., 2008).
5 . Modern Phytotherapy Ginseng species are adaptogens agents that increase general capacities to withstand situations of stress. P. quinquefolius is a noted adaptogen, inducing a reduction in stress and increase in physical performance over a period of time (Keville, 2000; Yarnell & Hooper, 2003). These adaptogenic effects are thought to assist in stress reduction via an influence on the hypothalamic- pituitary-adrenal (HPA) axis (Braun & Cohen 2010). Modern clinical applications include
1 4
hormone modulation for menopausal women, reduction and prevention of tumors in breast cancer patients and overall support for people living with HIV (Yarnell & Hooper, 2003). Additional uses include improving cerebral circulation, reducing fatigue and supporting healthy heart function (Keville, 2000; Yarnell & Hooper, 2003). The main therapeutic actions and clinical indications for P. quinquefolius are listed in Table 4. Table 4. Modern phytotherapeutic uses of P. quinquefolius. ACTIONS Adaptogen Antioxidant Sedative Mild stimulant Hypoglycemic Hepatoprotective Immunomodulatory Stomachic Tonic Aphrodisiac THERAPEUTIC INDICATIONS Weakness, deficient vitality, lethargy, convalescence Anxiety, depression, improve memory and concentration Physical and mental effects of ageing, sexual inadequacy Menopausal symptoms
1 5
Adjuvant for patients on cancer therapies, HIV Type II diabetes, hypoglycemia Anorexia Increase resistance to infections Orthostatic hypertension (Blumenthal, 2003; Green, 1991; Keville, 2000; Mills & Bone, 2000; Mitchell, 2003; Yarnell, Abascal, & Hooper 2003). Combinations With Rehmannia glutinosa (Gaertn.) DC. and Astragalus membranaceus Moench for debility, low grade fever and convalescence. With Turnera diffusa Willd. Ex Schult. and Serenoa serrulata (Michx.) Hook.f. ex B.D.Jacks. for sexual inadequacy in males (Green, 1991). With Avena sativa L. for nervous exhaustion
Contraindications Avoid in conditions manifested by acute inflammation or high fever or irritability.
Preparations and Dosage (Blumenthal, 2003; Keville, 2000; Yarnell et al., 2003). Powder: 0.30-10.0 grams, three times daily. Decoction: 3-6g dried root simmered in 750-1000mL water. Tincture: 2-4ml 3x a day Standardized extract (5:1) CNT2000: 2-300mg, 2-3 caps daily TCM dose: 1-9g (Bensky & Gamble, 1993).
Safety and toxicity P. quinquefolius is generally regarded as a safe herb, and is categorized as Class 1: herbs that can be safely consumed when used appropriately by the Botanical Safety Handbook (McGuffin, Hobbs, Upton, & Goldberg, 1997). Most of the literature concerning ginseng and safety is based on P. ginseng which is not a reliable predictor given known phytochemical differences between the two species (Kitts & Hu, 2000). The National Toxicological Program performed short-term toxicity, long term carcinogenicity and genetic toxicology in vivo studies on ginseng species and
1 6
found no evidence of toxicity (National Toxicology Program [NTP], 2004). In a Phase II clinical trial of 75 children with existing respiratory tract infections, safety data was generated and no significant adverse events were reported (Vohra et al., 2008). Charrios (2006) warns that the elderly may be at risk of exacerbating existing hypoglycaemia, and that diabetic subjects taking P. quinquefolius should monitor blood glucose more frequently. She also refers to potential severe effects of ginseng in general, but cites no examples or evidence (Charrios 2006). High doses do have the potential to cause nervousness or insomnia with both species (Jia et al., 2009).
P. quinquefolius does not appear to significantly affect cytochrome P450 enzymes, hence the risk of negative drug-herb reactions is relatively low. An in vitro study indicated inhibition of CYP3A4 was dependent on overall ginsenoside levels, however there was no such correlation with CYP2C9 (Luu, Foster, McIntyre, Tam, & Arnason, 2011). In one study on healthy human volunteers, a P. quinquefolius extract was combined with the HIV protease inhibitor drug Indinavir; there was no evidence of any pharmacokinetic interaction (Andriana et al., 2008).
Regulatory Status P. quinquefolius is regulated in the U.S.A. as a Dietary Supplement. In Canada it is regulated as Food, if no therapeutic claims are made, and New Drug if claims are made. 6. Sustainability Ecological status-RTE status On a global scale, P. quinquefolius is listed as G3-G4. States vary in their assessment of the status of ginseng and not all states have up-to-date plant surveys. Connecticut, Minnesota, Massachussets, and North Carolina list P. quinquefolius as of "special concern, Pennsylvania as vulnerable, Michigan and New Hampshire as threatened and Rhode Island as endangered. Tennessee lists P. quinquefolius as commercially exploited and does not include P. quinquefolius in its standard environmental review process. Landowners are advised that harvest is not sustainable (Tennessee Natural Heritage Program, 2008)
The Massachusetts DNR (n.d.) notes that across the nation, P quinquefolius is considered to be a locally threatened species because of over-harvesting, primarily for export to China. (See Appendix-1)
Harvesting & Collection regulations The collection, cultivation and trade of P. quinquefolius is governed at the county, state and federal level. The export of P. quinquefolius roots is regulated by the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) as an Appendix II species. Under the terms of CITES, the interstate and international trade is strictly controlled by the U.S. Fish and Wildlife Service. Interstate and international commerce records are required by the US Fish and Wildlife Service when permits are granted. These permits are limited to states that demonstrate adequate monitoring programs (U.S. Fish and Wildlife, 2011).
Continued approval for export from individual states is based on a determination by the U.S. Fish and Wildlife Service that exports will not be detrimental to the survival of the species.
Table 5. Harvesting regulations by state.
1 7
Licensing required Fee Harvesting Time Restrictions All states USFWS requires state agreement for any export
PA
1. Vulnerable Plant license Required for harvesting & for cultivation except when gathered for personal use, pleasure or direct to the consumer via farmers market 2. Harvester Certificate 3. PA Export Certificate 4. Dealer-Quarterly Reports 5. March 31- Weight slip for any unsold ginseng $50 Sept.1-Nov. 30 Only plants with at least three leaves having five leaflets each may be harvested and only if all berries are red. Berries must be planted at that site. April 1 to September 1 no one in PA shall possess green harvested ginseng roots (Burkhart & Jacobson, 2004). As of May 2002, individual State Forest Districts stopped issuing collection permits for ginseng and goldenseal. To determine if ginseng/goldenseal collection is permitted on State Forest land, contact the District Office in which collection is desired. NC 1. Dealers Permit a) Resident unlimited b) Resident limited (<100lbs) c) non-resident 2. Annual Dealer Reports 3. Export certificate & fee 4. Import certificate with state of origin 5. Certificate of cultivated ginseng
$100 $50 $500 --- $3/lb. Buying season Sept 1- Mar 31 Harvest Sept 1- Dec 1 Dealers permit from the Plant Industry Division Ginseng may not be sold outside the season, no exceptions ( the Statement indicating legal collection of ginseng from one's own land is no longer accepted) The certificate for cultivated ginseng - allows a grower to dig and sell ginseng at any time. The NCNFS (2005) sets the price per pound, offers permits from Sept 1 to Sept 30 which are good for 30 days only. Each permit allows a maximum of 3 pounds per person. The following states all have restrictions, licensing and permits which can be accessed on a state by state basis MA Protected from take (picking, collecting, killing...) and sale under the Massachusetts Endangered Species Act MN Sept1- Dec31 Ginseng harvest regulated under Minnesota Rules, Chapter 6282. Seeds are required to be planted, plants must have 3 prongs. KY license Aug 15- Dec1 HB 362, the "Ginseng bill went into effect June 8, 2011 There is $1,000 fine for buying ginseng from an unlicensed seller. Plants must have 3 prongs & seeds must be replanted. AL permit Sept 1- Dec13 Minimum age-3 prongs, seeds must be planted at site AR Sept 1- Dec 1 No harvesting on state lands, minimum age 5 years, 3 prongs, seeds must be planted at the site GA Aug 15-Dec 31 No harvesting on state lands, must have 3 prongs, seeds must be planted at the site IL 1st Sat in Sept- Nov 1 No harvesting on state lands, minimum age 10 years, 4 leafed, planting encouraged at the site.
1 8
IN Sept 1- Dec31 Does not require seeds to be replanted, plants must have 1. 3 prongs, 2. a flowering or fruiting stalk or 3. 4 internodes on root. Note: allows harvesting during flowering. IA Sept 1-Oct 31 Requires seeds to be replanted, plants must have 3 prongs Allows harvesting state forests, but not in state parks or preserves. MD Aug 20-Dec 1 Harvesting allowed in state forests, not in parks, Plants must be 5 years old with 3 prongs. MO Sept1-Dec 31 Seeds must be replanted, plants must have 3 prongs or fruiting stems NY Sept1-Nov 30 Seeds must be replanted, plants must have 3 prongs OH Sept 1- Dec31 Seeds must be replanted, plants must have 3 prongs TN Aug 15-Dec 31 Seeds must be replanted, plants must have be 5 years old with 3 prongs. VT Aug 20- Oct10 Seeds must be replanted, plants must have be 5 years old with 3 prongs. VA Aug 15- Dec31 Seeds are not required to be re-planted and plants must have a minimum of 3 prongs WV Sept 1- Nov 30 Seeds must be replanted, harvesting is limited to plants with 3 prongs WI Sept 1- Nov 1 Plants must have 3 prongs & mature fruit before they can be harvested, seeds must be replanted.
Export is currently regulated under the Convention on International Trade in Endangered Species of Wild Fauna & Flora Agreement.
Plants can only be exported if they are shown to be legally obtained in a fashion not detrimental to the survival of the species. States are given control over the management and certification for export of P. quinquefolius within their boundaries and are required to develop and implement a ginseng management program. They are required to submit specific export findings on a 3-year schedule (Michigan State University [MSU] Board of Trustees, 2004).
P. quinquefolius is on the United Plant Savers at risk' list and no wild harvest is recommended (Gladstar & Hirsch, 2000).
Market Data - Harvesting Impact, Tonnage Surveys Current 2011 market reports are available for a fee at Research and Markets http://www.researchandmarkets.com/reports/1330243/the_2011_import_and_export_market_for _ginseng The following data is from the American Herbal Products Association.
1 9
In 2008 roots gathered in the wild were being sold for as much as $1,000/pound of dried root or about $4/root (Janiskee, 2008).
Cultivation Habitat: Prefers rich hardwood forest with nutrient rich soils (Maine Department of Natural Resources [DNR], n.d.). Ginseng often occurs at the base of rock outcrops or on upland hill slopes where nutrient-rich soil has collected. Ginseng's medicinal and economic value varies according to how it has grown (Hertzog, 2010).
Cultivation: habitat 1. Wild Grown - These are plants that are naturally wild. They are considered to be the most valuable. Plant habitats are easily disturbed and plants may be damaged by campers, hikers or gatherers. 2. Wild-simulated- Seeds and rootlets are planted in a suitable habitat in its natural range. 3. Woods-grown- Seeds and rootlets are grown in woods similar in habitat to wild. 4. Field Cultivated - Seeds and rootlets are grown in fields with artificial shade. According to Herzog (2010) once ginseng has been grown and harvested from a field, it cannot be grown in that field again.
Habitat Natural range in natural habitat Within its natural range in suitable ginseng habitat grown in woods similar to natural habitat Grown in fields with artificial shade Cultivation None planting seeds & rootlets only Raised beds built for drainage Intensive human cultivation Fungicide none none extensive extensive Harvest Method Dug by hand Dug by hand Dug by machine Dug by machine Price/grade highest high medium low problems Selective harvests required to maintain population. may need to remove some forest canopy Pesticides & fertilizers. Not organic High labor costs Pesticides, fungicides, fertilizers subject to mold Organic Organic Not Organic Not organic
Cultivation: Seeds Ginseng begins to produce berries (each with two seeds) in the third year. These should be cold stratified and some sources suggest storing in damp sand for a year before planting. The law may require that seeds from wild-gathered plants be planted immediately in the area surrounding the original plants. Gathered seeds may be planted from the end of September until the end of February, and will germinate April/May. Plant seeds about 1/2" deep.
Cultivation: Roots Ginseng does not reproduce vegetatively. Two-year old roots will produce berries the following fall. Plant the roots about 1 1/2 inches deep, with the roots placed longways across the soil. Do not plant vertically. Cover the bed with mulch or rotten leaves.
Cultivation: Crop Treatments Canada maintains a list of chemicals that are approved for use with ginseng. 1. "Glyphosate application is usually recommended in the first few weeks of April. For glyphosate to work properly, the weeds should be green and actively growing. However, it is important to ensure that no ginseng has emerged above the soil, or it could be damaged. There have also been reports in the past that glyphosate residues on the straw can damage ginseng if it emerges into the straw shortly after application. Closely examine the stage of ginseng emergence before applying glyphosate products" (Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA), 2011.
2. "Quadris can be applied at any time and should be applied before ginseng begins to emerge for maximum protection from Rhizoctonia. Quadris can be extremely toxic to some varieties of apple and crabapple. Do not apply where there is the possibility of drift onto apple trees. Application before a rainfall will improve penetration of the product to the root zone" (OMAFRA, 2011).
3. "The first application of Bravo should be applied when the ginseng has 20% emerged.
2 1
For more information on ginseng pest management, consult OMAFRA Publication 610 Production Recommendations for Ginseng" (OMAFRA, 2011)
4. OMFRA (2011) also lists the following as approved for 2011: 1) Switch 62.5 WG Fungicide for the control of Botrytis blight (Botrytis cinerea) and Alternaria leaf blight (Alternaria panax) on ginseng in Canada. Restrictions include: A maximum of two (2) applications per season can be made at an interval of 7 10 days if conditions remain favourable for disease development. In general begin applications prior to or at the onset of disease. Do not apply within 7 days of harvest for ginseng. 2) Beleaf 50 SG Insecticide for the control of aphids. Allow a minimum of 7 days between applications. Do not apply more than 3 times per year.
Harvesting Roots should be dug in the fall after the above-ground parts die back. Take care to dig the entire root with all of its branches. Wash as soon as possible, but do not scrub.
Grower's Associations Appalachian Ginseng Foundation - http://www.a-spi.org/AGF/agfnl25.htm Northwest Ginseng Growers Association- http://www.nwginseng.org/home.html Ontario Ginseng Growers Association (OGGA)- http://www.ginsengontario.com/
7. Summary some possibilities moving forward More than any other herbal species, P. quinquefolius plays a significant role in the history, culture and economy of the Appalachian community. Until recently, research into therapeutic applications has been focused on the Asian counterpart (P. ginseng), however the last decade has seen a dramatic rise in the number of peer-reviewed publications investigating the biology, phytochemistry, pharmacology of the indigenous species, as well as clinic effects on humans. Initiatives such as the American Botanical Councils Ginseng Evaluation Program (Hall et al., 2001) which help to set standards for ginseng products are increasingly likely to focus on P. quinquefolius.
To date investigators have tended to focus on ginsenoside levels and their ratios in determining herb quality, and linking different ginsenosides to certain biological activities. It seems likely that levels of other constituents such as polyacetylenes and polysaccharides also influence quality and efficacy of P. quinquefolius, and that more focus should be placed on the use of whole root preparations, as well as of other plant sections. Now that a body of evidence is accumulating from laboratory and animal studies including safety data, there is a need for more human studies focusing on the potential benefits for cognition and memory, metabolic impairment, stress, fatigue and immune deficient disorders.
2 2
Finally, any research on the benefits to human health of P. quinquefolius needs to be paralleled by research on sustainable cultivation of this valuable Appalachian resource as well as policies that ensure the maintenance and growth of wild populations and native habitat.
8. References
Agriculture and AGri-Food Canada. (2007). Ginseng statistics. Retrieved from: http://www4.agr.gc.ca/AAFC-AAC/display-afficher.do?id=1174495359716&lang=eng
American Herbal Products Association (AHPA). (2007). Tonnage Survey of Select North American wild-harvested plants, 2004-2005. Silver Spring, MD: The American Herbal Products Association
Andriana, A.S.A., Hendrix, C., Parsons, T.L., Caballero, B., Yuan, C., Flexner, C.W., Dobs, A.S., & Brown, T.T. (2008). Pharmacokinetic and metabolic effects of American ginseng (P. quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinivar. BMC Comp and Alt Med 8, 1-10.
Assinewe, V. A., Amason, J. T., Aubry, A., Mullin, J., & Lemaire, I. (2002). Extractable polysaccharides of Panax quinquefolius L. (North American ginseng) root stimulate TNFalpha production by alveolar macrophages. Phytomedicine 9 (5), 398-404.
Assinewe, V. A., Baum, B. R., Gagnon, D., and Arnason, J. T. (2003). Phytochemistry of wild populations of Panax quinquefolius L. (North American Ginseng). Journal of Agricultural and Food Chemistry 51, (16), 4549-4553.
Attele, A. S., Zhou, Y.-P., Xie, J.-T., Wu, J. A., Zhang, L., Dey, L., Pugh, W., Rue, P. A., Polonsky, K. S., & Yuan, C.-S. (2002). Antidiabetic Effects of Panax ginseng Berry Extract and the Identification of an Effective Component. Diabetes 51, (6), 1851 -1858.
Awang, D. V. C. (2000). The Neglected Ginsenosides of North American Ginseng (Panax quinquefolius L.). J. Herbs, Spices & Medicinal Plants 7 (2), 103.
Babish, J. G., Pacioretty, L. M., Bland, J. S., Minich, D. M., Hu, J., & Tripp, M. L. (2010). Antidiabetic screening of commercial botanical products in 3T3-L1 adipocytes and db/db mice. J.Medicinal Food 13( 3), 535-547.
Bae, E.-A., Han, M. J., Kim, E.-J., & Kim, D.-H. (2004). Transformation of ginseng saponins to ginsenoside rh2 by acids and human intestinal bacteria and biological activities of their transformants. Archives of Pharmacal Research 27,1, 61-67.
Bae, E.-A., Han, M. J., Choo, M.-K., Park, S.-Y., & Kim, D.-H. (2002). Metabolism of 20(S)- and 20(R)-Ginsenoside Rg3 by Human Intestinal Bacteria and Its Relation to in Vitro Biological Activities. Biological & Pharmaceutical Bulletin 25 (1), 58.
Banks, W. (2004). Plants of the Cherokee. Great Smokey Mountain Association.
2 3
Banz, W. J., Iqbal, M. J., Bollaert, M., Chickris, N., James, B., Higginbotham, D. A., Peterson, R., Murphy, L. (2007). Ginseng modifies the diabetic phenotype and genes associated with diabetes in the male ZDF rat. Phytomedicine 14 (10), 681-689.
Barton, D. L., Soori, G. S., Bauer, B. A., Sloan, J. A., Johnson, P. A., Figueras, C., Duane, S., Mattar, B., Liu, H., Atherton, P.J., Christensen, B., & Loprinzi, C.L. (2009). Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Supportive Care in Cancer 18 (2), 179-187.
Benishin, C. G., Lee, R., Wang, L. C. H., & Liu, H. J. (1991). Effects of Ginsenoside Rbi on Central Cholinergic Metabolism. Pharmacology 42 (4). 223-229.
Bensky, D. & Gamble, A. 1993. Chinese herbal medicine materia medica (Rev. ed.). Seattle, WA: Eastland Press.
Bernards, M. A., Ivanov, D. A., Neculai, M. A., & Nicol, R. W. (2011). Ginsenoside variation within and between Ontario ginseng landraces: Relating phytochemistry to biological activity. In The Biological activity of phytochemicals, Recent advances in phytochemistry 41, 97-107. New York, NY: Springer.
Biondo, P. D., Robbins, S. J., Walsh, J. D., McCargar, L. J., Harber, V. J., & Field, C. J. (2008). A randomized controlled crossover trial of the effect of ginseng consumption on the immune response to moderate exercise in healthy sedentary men. Applied Physiology, Nutrition, and Metabolism 33 (5), 966-975.
Blumenthal, M. (2003). The ABC Clinical Guide to Herbs. Austin, TX: American Botanical Council.
Braun, L. & Cohen, M. (2010). Herbs and natural supplements. an evidence-based guide ( 3 rd . ed.). Sydney, Australia: Churchill Livingstone Elsevier.
Burkhart, E. & Jacobson, M. (2004). American ginseng. Nontimber forest products (NTFPs) from Pennsylvania, Series #1: State College, PA: Pennsylvania State University. Retrieved from http://www.dcnr.state.pa.us/forestry/wildplant/ginsengregulations.aspx
Case, M. A., Flinn, K. M., Jancaitis, J., Alley, A., and Paxton, A. (2007). Declining abundance of American ginseng (Panax quinquefolius L.) documented by herbarium specimens. Biological Conservation 134 (1), 22-30.
Cavender, A. (2003). Folk medicine in southern Appalachia. Chapel Hill, NC: The University of North Carolina Press.
2 4
Chen, X.-C., Chen, Y., Zhu, Y.-G., Fang, F., & Chen, L.-M. (2002). Protective effect of ginsenoside Rg1 against MPTP-induced apoptosis in mouse substantia nigra neurons. Acta Pharmacol Sin 23 (9), 829-834.
Chen, X.-C., Zhu. Y.-G., Zhu, L.-A., Huang, C., Chen, Y., Chen, L.-M., Fang, F., Zhou, Y.-C., & Zhao, C.-H. (2003). Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress. European Journal of Pharmacology 473 (1), 1-7.
Chen, J.K. and Chen, T.T. 2004. Chinese medical herbology and pharmacology. City of Industry, Ca: Art of Medicine Press.
Christensen, L. P. & Jensen, M. (2008). Biomass and content of ginsenosides and polyacetylenes in American ginseng roots can be increased without affecting the profile of bioactive compounds. Journal of Natural Medicines 63 (2),159-168.
Christensen, L. P., Jensen, M., & Kidmose, U. (2006). Simultaneous Determination of Ginsenosides and Polyacetylenes in American Ginseng Root (Panax quinquefolium L.) by High-Performance Liquid Chromatography. Journal of Agricultural and Food Chemistry 54 (24), 8995-9003.
Cook, W. (1869). The physiomedical dispensatory: A treatise on therapeutics, materia medica and pharmacy. Cincinnati OH. Pub. by the author.
Corbit, R., Ebbs, S., King, M. L., & Murphy, L. L. (2006). The influence of lead and arsenite on the inhibition of human breast cancer MCF-7 cell proliferation by American ginseng root (Panax quinquefolius L.) Life Sciences, 78 (12), 1336.
Crellin, J.K., & Philpott, J. (1990). A reference guide to medicinal plants. Durham, NC: Duke University Press.
Cruse-Sanders, J. M., & Hamrick, J. L. (2004). Genetic diversity in harvested and protected populations of wild American ginseng, Panax quinquefolius L. (Araliaceae). American Journal of Botany 91 (4), 540 -548.
Dascalu, A., Sievenpiper, J., Jenkins, A., Stavro, M., Leiter, L., Arnason, J., & Vuksan, V. (2007). Five batches representative of Ontario-grown American ginseng root produce comparable reductions of postprandial glycemia in healthy individuals. Canadian Journal of Physiology and Pharmacology 85, 856-864.
Duda, R. B., Taback, B., Kessel, B., Dooley, D. D., Yang, H., Marchiori, J., Slomovic, B. M., & Alvarez, J. G. (1996). pS2 expression induced by American ginseng in MCF-7 breast cancer cells. Annals of Surgical Oncology 3 (6), 515-520.
2 5
Duda, R. B., Zhong, Y., Navas, V., Li, M. Z., Toy, B. R., & Alavarez, J. G. (1999). American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. Journal of Surgical Oncology 72 (4), 230-239.
Duda, R. B., Kang, S. S., Archer, S. Y., Meng, S., & Hodin, R. A. (2001). American ginseng transcriptionally activates p21 mRNA in breast cancer cell lines. Journal of Korean Medical Science 16 (Suppl.), S54-60.
Duke, J. (1986). Handbook of northeastern indian medicinal plants. Lincoln, MA, Quarterman Publications, Inc.
Elliot, D.B. (1976). An Underground Botany and Foragers Guide. CT: Chatham Press.
Farms.com. (2011). Millions in losses for local ginseng growers. Retrieved from http://www.farms.com/FarmsPages/ENews/NewsDetails/tabid/189/Default.aspx?NewsID =41265
Felter, H.W. (1922). The eclectic materia Medica, pharmacology & therapeutics. Portland, OR. : Eclectic Medical Publications.
Felter, H., & Lloyd, J. (1898). Kings American Dispensatory (18th ed.., 3rd rev.). Portland,OR: Eclectic Medical Publications.
Ferreira, J. F. S., Ebbs, S. D., Murphy, L. L., & Corbit, R. M. (2005). Simplified extraction of ginsenosides from American ginseng (Panax quinquefolius L.) for high-performance liquid chromatography-ultraviolet analysis. J Agric Food Chem 53 (26), 9867-73.
Foster, S. & Johnson, R.L. (2006). Desk reference to natures medicine. Washington D.C.: National Geographic.
Fourniera, A. R., Proctorb, J. T. A., Gauthierc, L., Khanizadehd, S., Blangerd, A., Gosselina A., & Dorais, M. (2003). Understory light and root ginsenosides in forest-grown Panax quinquefolius. Phytochemistry 63 (7), 777-782.
Fu, Y., & Ji, L. L. (2003). Chronic Ginseng Consumption Attenuates Age-Associated Oxidative Stress in Rats. The Journal of Nutrition 133 (11), 3603 -3609.
Fujimoto, Y., Satoh, M., Takeuchi, N., & Kirisawa, M. (1991). Cytotoxic acetylenes from Panax quinquefolium. Chemical & Pharmaceutical Bulletin 39 (2), 521-523.
Fujimoto, Y., Wang, H., Kirisawa, M., Satoh, M., & Takeuchi, N. (1992). Acetylenes from Panax quinquefolium. Phytochemistry 31 (10), 3499-3501.
Fujimoto, Y., Wang, H., Satoh, M., & Takeuchi, N. (1994). Polyacetylenes from Panax quinquefolium. Phytochemistry 35 (5),1255-1257.
2 6
Green, J. (1991). The male herbal. California: Crossing Press.
Groves, R. (2010). Integrated pest management of ginseng. University of Wisconsin, Department of Entomology. Retrieved from http://www.entomology.wisc.edu/vegento/xtras/ppt/2010_ginseng.pdf
Han, B., Park, M., Han, Y., Woo, L., Sankawa, U., Yahara, S., & Tanaka, O. (1982). Degradation of Ginseng Saponins under Mild Acidic Conditions. Planta Medica 44 (03), 146-149.
Harding, A.R. (1936). Ginseng and other medicinal Plants. Columbus, OH: A.R.Harding.
Harkey, M. R., Henderson, G. L., Gershwin, M. E., Stern, J. S., & Hackman, R. M. (2001). Variability in commercial ginseng products: an analysis of 25 preparations. The American Journal of Clinical Nutrition 73 (6), 1101 -1106.
Herzog, K. (2010). Buyers from across the world are camped out in Marathon County for crop. Journal Sentinel, (October 10, 2010). Retrieved from http://www.jsonline.com/news/wisconsin/105114499.html
Howell, P. (2006). Medicinal plants of the southern Appalachians. Mountain City, GA: BotanoLogos Books.
Ichikawa, T., Li, J., Nagarkatti, P., Nagarkatti, M., Hofseth, L. J., Windust, A., & Cui, T. (2009). American ginseng preferentially suppresses STAT/iNOS signaling in activated macrophages. Journal of Ethnopharmacology 125 (1), 145-150.
Jia, L., Zhao, Y., & Liang, X. J. (2009). Current evaluation of the millennium phytomedicine- ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Current Medicinal Chemistry 16 (22), 2924-2942.
Janiskee, B. (2008). Sky-high ginseng prices boost illegal harvest in Blue Ridge Parkway and Great Smoky Mountain National Park. Retrieved from http://www.nationalparkstraveler.com (Note: this online journal also contains commentary from wild harvesters through 2010).
Jochum, G. M., Mudge, K. W. M, & Thomas, R. B. (2007). Elevated temperatures increase leaf senescence and root secondary metabolite concentrations in the understory herb Panax quinquefolius (Araliaceae). Am. J. Bot. 94 (5), 819-826.
2 7
Keville, K. (2000). Panax quinquefolius. In R. Gladstar & P. Hirsch (Eds.) Planting the future: saving our medicinal herbs. Rochester, VT: Healing Arts Press
Kim, H.-S., Lee, E.-H., Ko, S.-R., Choi, K.-J., Park, J.-H., & Im, D.-S. (2004). Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Archives of Pharmacal Research 27 (4), 429-435.
Kim, H. Y., Kang, K. S., Yamabe, N., Nagai, R., & Yokozawa, T. (2007). Protective effect of heat-processed American ginseng against diabetic renal damage in rats. Journal of Agricultural and Food Chemistry 55 (21), 8491-8497.
Kim, M. K., Lee, J. W., and Lee, K. Y. (2005). Microbial conversion of major ginsenoside Rb1 to pharmaceutically active minor ginsenoside. J Microbiol 43 (5), 456-462.
King, M. L., Adler, S. R., & Murphy, L. L. (2006). Extraction-Dependent Effects of American Ginseng (Panax quinquefolium) on Human Breast Cancer Cell Proliferation and Estrogen Receptor Activation. Integrative Cancer Therapies, 5(3), 236 -243.
King, M. L. & Murphy, L. L. (2007). American ginseng (Panax quinquefolius L.) extract alters mitogen-activated protein kinase cell signaling and inhibits proliferation of MCF-7 cells. Journal of Experimental Therapeutics & Oncology 6 (2), 147-155.
King, M. L. & Murphy, L. L. (2010). Role of cyclin inhibitor protein p21 in the inhibition of HCT116 human colon cancer cell proliferation by American ginseng (Panax quinquefolius) and its constituents. Phytomedicine 17, 3-4.
Kitts, D. & Hu, C. (2000). Efficacy and safety of ginseng. Public Health Nutrition 3, 473-485.
Kyu L. H., Jung, M. H., Sohn, J. H., & Hwang, J.-K. (2006). Ginsenoside 20(S)- Protopanaxatriol (PPT) Activates Peroxisome Proliferator-Activated Receptor (PPAR) in 3T3-L1 Adipocytes. Biological & Pharmaceutical Bulletin 29 (1), 110-113.
Lee, Y. J., Chung, E., Lee, K. Y., Lee, Y. H., Huh, B, & Lee, S. K. (1997). Ginsenoside-Rg1, one of the major active molecules from Panax ginseng, is a functional ligand of glucocorticoid receptor. Molecular and Cellular Endocrinology 133 (2),135-140.
Lee, Y. J., Jin, Y. R., Lim, W. C., Ji, S. M., Choi, S., Jang, S., & Lee, S. K. (2003). A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells. The Journal of Steroid Biochemistry and Molecular Biology 84 (4), 463-468.
Leung, K. & Wong, A. (2010a). Pharmacology of ginsenosides: a literature review. Chinese Medicine 5, 1-7.
2 8
Leung, K. W., Cheng, Y.-K., Mak, N. K., Chan, K. K. C., Fan, T.P. D., & Wong, R. N.S. (2006). Signaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells. FEBS Letters 580, (13), 3211-3216.
Li, W. & Fitzloff, J. F. (2001). Determination of 24(R)-pseudoginsenoside F11 in North American ginseng using high performance liquid chromatography with evaporative light scattering detection. Journal of Pharmaceutical and Biomedical Analysis 25 (2), 257- 265.
Li, Y.-G., Chen, M., Chou, G.-X., Want, Z.-T., & Hu, Z.-B. (2004). Ruggedness/robustness evaluation and system suitability test on United States Pharmacopoeia XXVI assay ginsenosides in Asian and American ginseng by high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis 35 (5),1083-1091.
Li, Z., Guo, Y. Y., Wu, C. F., Li, X., & Wang, J. H. (1999). Protective effects of pseudoginsenoside-F11 on scopolamine-induced memory impairment in mice and rats. The Journal of Pharmacy and Pharmacology 51 (4),435-440.
Liu, Y., Zhang, J.-W., Li, W., Ma, H., Sun, J., Deng, M.-C., & Yang, L. (2006). Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicological Sciences 91 (2),: 356 -364.
Luu, A., Foster, B. C., McIntyre, K. L., Tam, T. W., Arnason, J. T. (2011). Pharmacogenetics in potential herb-drug interactions: effects of ginseng on CYP3A4 and CYP2C9 allelic variants. In D.R. Gang (Ed.). The Biological Activity of Phytochemicals (59-65). New York, NY: Springer.
Massachusetts Division of Fisheries and Wildlife. (n.d.). Ginseng, Panax quinquefolius. Natural Heritage Endangered Species Program. Retrieved from http://www.mass.gov/dfwele/dfw/nhesp/species_info/nhfacts/panexquinquefolius.pdf
McElhaney, J. E., Gravenstein, S., Cole, S. K., Davidson, E., ONeill, D., Petitjean, S., Rumble, B., & Shan, J. J. (2004). A PlaceboControlled Trial of a Proprietary Extract of North American Ginseng (CVTE002) to Prevent Acute Respiratory Illness in Institutionalized Older Adults. Journal of the American Geriatrics Society 52 (1),13-19.
McGraw, J. B., Sanders, S. M., and Van der Voort, M. (2003). Distribution and Abundance of Hydrastis canadensis L. (Ranunculaceae) and Panax quinquefolius L. (Araliaceae) in the Central Appalachian Region. Journal of the Torrey Botanical Society 130 (2), 62-69.
McGuffin, M., Hobbs, C., Upton, R., & Goldberg, A. (Eds.). (1997). Botanical Safety Handbook. Boca Raton, FL: CRC Press,
Miller, S. C., Delorme, D., & Shan, J. J. (2009). CVT-E002 stimulates the immune system and extends the life span of mice bearing a tumor of viral origin. Retrieved from
Mills, S. & Bone, K. (2000). Principles and Practice of Phytotherapy. Edinburgh, UK: Churchill Livingstone.
Millspaugh, C.F. (1974). American Medicinal Plants. New York, NY: Dover Publications.
Mitchell, W. (2003). Plant Medicine in Practice. St. Louis, MO: Churchill Livingstone,.
Moerman, D. (1998). Native American Ethnobotany. Portland, OR: Timbre Press, Inc.
Murphy, L. (2002). American ginseng in the prevention and treatment of human breast cancer. Report to U.S. Report Carbondale, IL: Southern Illinois University.
National Toxicology Program. (2004). Summary of Data for Ginseng and Ginsenosides 5067- 080-0, vol. 2004. Washington, DC: National Toxicology Program, National Institute of Health.
North Carolina National Forest Service (NCNFS). (2005). Saleable special forest products, 87.51b- Exhibit 01. Forest Service handbook. Asheville, NC: North Carolina National Forest (Region 8), USDA Forest Service. Retrieved from http://www.fs.usda.gov/Internet/FSE_DOCUMENTS/stelprdb5188146.pdf
Ontario Ministry of Agriculture, Food and Rural Affairs. (2011). Ginseng and specialty crop report for April 19, 2011. Retrieved from http://apps.omafra.gov.on.ca/scripts/english/crops/agriphone/article.asp?ID=1963
Orsat, V. & Dai, J. (2010). Extraction of Ginsenosides from American Ginseng (Panax quinquefolium L.) Root. International Journal of Food Engineering 6 (3),1-18
Papapetropoulos, A. (2007). A ginseng-derived oestrogen receptor (ER) agonist, Rb1 ginsenoside, attenuates capillary morphogenesis. British Journal of Pharmacology 152 (2) .172-174.
Penskar, M.R. & P.J. Higman. (1996). Special plant abstract for Panax quinquefolius (ginseng). Lansing, MI: Michigan Natural Features Inventory.
Pennsylvania Department of Natural Resources. (2011). Ginseng Regulations. Harrisburg,Pennsylvania: The Pennsylvania Wild Plant Program. Retrieved from http://www.dcnr.state.pa.us/forestry/wildplant/ginsengregulations.aspx
Predy, G. N., Goel, V., Lovlin, R., Donner, A., Stitt, L., & Basu, T. K. (2005). Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: a randomized controlled trial. CMAJ 173 (9),1043-1048.
3 0
Qi, L.-W., Wang, C.-Z., & Yuan, C.-S. (2010). American ginseng: Potential structure-function relationship in cancer chemoprevention Biochemical Pharmacology 80 (7), 947-954.
Qi, L.-W., Wang, C.-Z., & Yuan, C.-S. (2011). Isolation and analysis of ginseng: advances and challenges. Natural product reports 28 (3), 467-495.
Radad, K., Gille, G., Moldzio, R., Saito, H., Ishige, K., & Rausch, W.-D. (2004). Ginsenosides Rb1 and Rg1 effects on survival and neurite growth of MPP + -affected mesencephalic dopaminergic cells. Journal of Neural Transmission 111 (1), 37-45.
Radad, K., Gille, G., Liu, L., & Rausch, W-D. (2006). Use of Ginseng in Medicine With Emphasis on Neurodegenerative Disorders. Journal of Pharmacological Sciences 100 (3), 175-186.
Rausch, W.-D., Liu, S., Gille, G., & Radad, K. (2006). Neuroprotective effects of ginsenosides. Acta Neurobiol Exp 66,369-375.
Reeds, D. N., Patterson, B. W., Okunade, A., Holloszy, J. O., Polonsky, K. S., & Klein, S. (2011). Ginseng and Ginsenoside Re Do Not Improve -Cell Function or Insulin Sensitivity in Overweight and Obese Subjects With Impaired Glucose Tolerance or Diabetes. Diabetes Care 34 (5),1071 -1076.
Remington, J.P. & Wood, H.C. (1918). The Dispensatory of the United States. 20 th ed.
Roy, R., Grohs, R., & Reeleder, R. (2003). A method for the classification by shape of dried roots of ginseng (Panax quinquefolius L.) Canadian Journal of Plant Science 83, 955- 958.
Rudakewich, M., Ba, F., & Benishin, C. G. (2001). Neurotrophic and Neuroprotective Actions of Ginsenosides Rb1 and Rg1. Planta Medica 67 (6), 533-537.
Rural Action Inc. (2005). Plants to Watch Panax quinquefolium L. Retrieved from http://www.appalachianforest.org/ptw_ginseng.html
Sala, F., Mulet, J., Choi, S., Jung, S.-Y., Nah, S.-Y., Rhim, H., Valor, L. M., Criado, M., & Sala, S. (2002). Effects of Ginsenoside Rg2 on Human Neuronal Nicotinic Acetylcholine Receptors. Journal of Pharmacology and Experimental Therapeutics 301 (3), 1052 - 1059.
Satoh, Y., Satoh, M., Isobe, K., Mohri, K., Yoshida, Y., & Fujimoto, Y. (2007). Studies on Panax Acetylenes: Absolute Structure of a New Panax Acetylene, and Inhibitory Effects of Related Acetylenes on the Growth of L-1210 Cells. Chemical & Pharmaceutical Bulletin 55 (4), 561-564.
3 1
Schlag, E. M. (2004). Genetic diversity and phytochemistry of Maryland-grownamerican ginseng (panax quinquefoliusL.). MS Thesis, College Park: University of Maryland.
Schlag, E. M., and McIntosh, M. S. (2006). Ginsenoside content and variation among and within American ginseng (Panax quinquefolius L.) populations. Phytochemistry 67 (14),1510- 1519.
Scholey, A., Ossoukhova, A., Owen, L., Ibarra, A., Pipingas, A., He, K., Roller, M., & Stough, C. (2010). Effects of American ginseng (Panax quinquefolius) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled, crossover study. Psychopharmacology 212 (3),345-356.
Scudder, J. (1870). Specific Medication and Specific Medicines. Cincinnati,OH: Wilstach, Baldwin & Co.
Sengupta, S., Toh, S.-A., Sellers, L. A., Skepper, J. N., Koolwijk, P., Leung H. W., Yeung, H.- W., Wong, R. N.S., Sasisekharan, R., and Fan, T.-P. D. (2004). Modulating Angiogenesis: The Yin and the Yang in Ginseng. Circulation 110 (10), 1219-1225.
Shan, J. J., Rodgers, K., Lai, C. T., & Sutherland, S. K. (2007). Challenges in natural health product research: The importance of standardization. Proceedings of the Western Pharmacology Society 50, 24-30.
Shang, W., Yang, Y., Jiang, B., Jin, H., Zhou, L., Liu, S., & Chen, M. (2007). Ginsenoside Rb1 promotes adipogenesis in 3T3-L1 cells by enhancing PPAR[gamma]2 and C/EBP[alpha] gene expression. Life Sciences 80 (7),618-625.
Shang, W., Yang, Y., Zhou, L., Jiang, B., Jin, H., & Chen, M. (2008). Ginsenoside Rb1 stimulates glucose uptake through insulin-like signaling pathway in 3T3-L1 adipocytes. Journal of Endocrinology 198 (3), 561 -569.
Seida, J. K., Durec, T., & Kuhle, S. (2009). North American (Panax quinquefolius) and Asian Ginseng (Panax ginseng) Preparations for Prevention ofthe CommonCold inHealthyAdults: A Systematic Review. Evidence-Based Complementary and Alternative Medicine: eCAM 2011, 1-7.
Sievenpiper, J. L., Arnason, J. T., Leiter, L. A., & Vuksan, V. (2003). Null and Opposing Effects of Asian Ginseng (Panax ginseng C.A. Meyer) on Acute Glycemia: Results of Two Acute Dose Escalation Studies. Journal of the American College of Nutrition 22, 6 , 524 -532.
Sievenpiper, J. L., Arnason, J. T., Leiter, L. A., & Vuksan, V. (2004). Decreasing, Null and Increasing Effects of Eight Popular Types of Ginseng on Acute Postprandial Glycemic Indices in Healthy Humans: The Role of Ginsenosides. Journal of the American College of Nutrition 23, 3, 248 -258.
3 2
Sun, C., Li, Y., Wu, Q., Luo, H., Sun, Y., Song, J., Liu, E., & Chen, S. (2010). De novo sequencing and analysis of the American ginseng root transcriptome using a GS FLX Titanium platform to discover putative genes involved in ginsenoside biosynthesis. BMC Genomics 11 (1), 262.
Taylor, D.A. (2006). Ginseng, the Divine Root. Chapel Hill, NC: Algonquin Books of Chapel Hill.
Tennessee Natural Heritage Program. (2008). Rare Plant List. Nashville, Tennessee: Department of Environment and Conservation, Division of Natural Areas. Retrieved from http://www.state.tn.us/environment/na/pdf/plant_list.pdf
USP. (2004). USP 27 NF22. Rockville MD: United States Pharmacopeial Convention Inc.
U.S. Fish and Wildlife Service, International Affairs. (2011). Convention Permit Applications for Ginseng. Finding(s) on the export of American ginseng, Panax quinquefolius, harvested in the Fall 2000. Retrieved from http://www.fws.gov/international/dma_dsa/CITES/plants/findings_00.html
Van Der Voort, M. E., Bailey, B., Samuel, D. E., and McGraw, J. B. (2003). Recovery of Populations of Goldenseal (Hydrastis canadensis L.) and American Ginseng (Panax quinquefolius L.) Following Harvest. The American Midland Naturalist 149 (2),282- 292.
Vohra, S., Johnston, B. C., Laycock, K. L., Midodzi, W. K., Dhunnoo, I., Harris, E., & Baydala, L. (2008). Safety and tolerability of North American ginseng extract in the treatment of pediatric upper respiratory tract infection: a phase II randomized, controlled trial of 2 dosing schedules. Pediatrics 122 (2),402-410.
Vuksan, V., Stavro, M. P., Sievenpiper, J. L., Beljan-Zdravkovic, U., Leiter, L. A., Josse, R. G., & Xu, Z. (2000). Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care 23, 9 ,1221 - 1226.
Vuksan, V., Stavro, M. P., Sievenpiper, J. L., Koo, V. Y. Y., Wong, E., Beljan-Zdravkovic, U., Francis, T., Jenkins, A.L.. Leiter, L.A., Josse, R.G. Xu, Z. (2000). American Ginseng Improves Glycemia in Individuals with Normal Glucose Tolerance: Effect of Dose and Time Escalation. Journal of the American College of Nutrition 19 (6), 738 -744.
Vuksan, V., Sievenpiper, J. L., Wong, J., Xu, Z., Beljan-Zdravkovic, U., Arnason, J. T., Assinewe, V., Francis, T. (2001). American ginseng (Panax quinquefolius L.) attenuates postprandial glycemia in a time-dependent but not dose-dependent manner in healthy individuals. The American Journal of Clinical Nutrition 73 (4), 753-758.
Wan, J., Li, S., Chen, J., & Wang, Y. (2007). Chemical characteristics of three medicinal plants of the Panax genus determined by HPLC-ELSD. J. Sep. Sci. 30.
3 3
Wang, C. L., Shi, D. Z., & Yin, H. J. (2007). Effect of panax quinquefolius saponin on angiogenesis and expressions of VEGF and bFGF in myocardium of rats with acute myocardial infarction. Chinese Journal of Integrated Traditional and Western Medicine 27 (4),: 331-334.
Wang, C.-Z., Zhang, B., Song, W.-X., Wang, A., Ni, M., Luo, X., Aung, H. H., et al. (2006). Steamed American ginseng berry: ginsenoside analyses and anticancer activities. Journal of Agricultural and Food Chemistry 54 (26),9936-9942.
Wang, M., Guilbert, L. J., Ling, L., Li, J., Wu, Y., Xu, S., Pang, P., & Shan, J. J. (2001). Immunomodulating activity of CVTE002, a proprietary extract from North American ginseng (Panax quinquefolium). Journal of Pharmacy and Pharmacology 53 (11), 1515- 1523.
Wang, M., Guilbert, L. J., Li, J., Wu, Y., Pang, P., Basu, T. K., & Shan, J. J. (2004). A proprietary extract from North American ginseng (Panax quinquefolium) enhances IL-2 and IFN-[gamma] productions in murine spleen cells induced by Con-A. International Immunopharmacology 4 (2),311-315.
WildGrown.com. (2011). Differing ginseng types depends on how its grown. National ginseng, LLC. Retrieved from http://www.wildgrown.com/index.php/Ginseng-Articles/Growing- Ginseng/Different-Ginseng-Types-Depends-on-How-Its-Grown.html
Wood, G. B. & Bache, F. (1858). The dispensatory of the United States of America (11 th ed.). Philadelphia, PA: J. B. Lippencott and Co. Wu, C. F., Liu, Y. L., Song, M., Liu, W., Wang, J. H., Li, X., & Yang, J. Y. (2003). Protective effects of pseudoginsenoside-F11 on methamphetamine-induced neurotoxicity in mice. Pharmacology Biochemistry and Behavior 76 (1), 103-109.
Xie, G., Plumb, R., Su, M., Xu, Z., Zhao, A., Qiu, M., Long, X., Liu, Zx, & Jia, W. (2008). Ultraperformance LC/TOF MS analysis of medicinal Panax herbs for metabolomic research. Journal of Separation Science 31, 67, 1015-1026.
Xie, J.-T., Mehendale, S. R., Wang, A., Han, A. H., Wu, J. A., Osinski, J., & Yuan, C.-S. (2004). American ginseng leaf: ginsenoside analysis and hypoglycemic activity. Pharmacological Research: The Official Journal of the Italian Pharmacological Society 49 (2),113-117.
Xie, J.-T., Wu, J. A., Mehendale, S., Aung, H. H., & Yuan, C. S. (2004). Anti-hyperglycemic effect of the polysaccharides fraction from American ginseng berry extract in ob/ob mice. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 11 (2-3), 182-187.
Xie, J.-T., Mehendale, S., & Yuan, C.-S. (2005). Ginseng and diabetes. The American Journal of Chinese Medicine 33 (3). 397-404.
3 4
Xiong, Y., Shen, L., Liu, K. J., Tso, P., Xiong, Y., Wang, G., Woods, S. C., & Liu, M. (2010). Antiobesity and Antihyperglycemic Effects of Ginsenoside Rb1 in Rats. Diabetes 59 (10) ,2505 -2512.
Xu, T.-M., Cui, M.-H., Xin, Y., Gu, L.-P., Jiang, X., Su, M.-M., Wang, D.-D., & Wang, W.-J. (2008). Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chinese Medical Journal 121 (15), 1394-1397.
Yarnell, E., Abascal, K., Hooper, G. C. (2003). Clinical Botanical Medicine. Larchmont, NY: Mary Ann Liebert, Inc.
Yat, P. N., Arnason, J. T., Lu, Z. Z., Fitzloff, J. F., Fong, H. H. S., & Awang, D. V. C. (1998). HPLC methods for separation and quantitative determination of ginsenosides used in the American Botanical Councils ginseng evaluation program.
Yoon, M., Lee, H., Jeong, S., Kim, J.-J., Nicol, C. J., Nam, K. W., Kim, M., Cho, B. G., & Oh, G. T. (2003). Peroxisome proliferator-activated receptor is involved in the regulation of lipid metabolism by ginseng. British Journal of Pharmacology 138 (7), 1295-1302.
Yoshikawa, M., Murakami, T., Yashiro, K., Yamahara, J., Matsuda, H., Saijoh, R., & Tanaka, O. (1998). Bioactive saponins and glycosides. XI. Structures of new dammarane-type triterpene oligoglycosides, quinquenosides I, II, III, IV, and V, from American ginseng, the roots of Panax quinquefolium L. Chemical & Pharmaceutical Bulletin 46 (4),647- 654.
Yuan, C.-S., Wang, C.-Z., Wicks, S. M., & Qi, L.-W. (2010). Chemical and pharmacological studies of saponins with a focus on American ginseng. Journal of ginseng research 34 (3), 160-167.
Zhou, D.L., & Kitts, D.D. (2002). Peripheral blood mononuclear cell production of TNF- in response to North American ginseng stimulation. Canadian Journal of Physiology and Pharmacology 80,1030-1033.
Appendix 1 . Endangered, threatened, rare status
Global G3-G4 Michigan Natural Features Inventory. 1999. Michigan's special plants (20 October 2002). Michigan Department of Natural Resources, Michigan. Updated list (April 9, 2009) US federal CT Sc special concern Endangered, threatened & special concern plants (10 July, 2010). State of Connecticut, Connecticut. http://www.ct.gov/dep/cwp/view.asp?a=2702&q=323482&depNav_GID=1628 MI threatened S2S3 Michigan Natural Features Inventory. 1999. Michigan's special plants (20 October 2002). Michigan Department of Natural Resources, Michigan. Updated list (April 9, 2009)
3 5
NY S3-S4 New York, Department of Environmental Conservation. (2010) 2010 New York Rare Plant Status Lists. http://www.dec.ny.gov/docs/fish_marine_pdf/2010rareplantstatus.pdf New York notes that they do not have a current count for ginseng and need such. Maine S3 Maine Department of Conservation, Natural Areas Program, Rare Plants. P. Quinquefolius last observation date: 2002 RI SE Rhode Island, one extant population. SE, G4, Rhode ISland Rare PLants (2007) http://www.rinhs.org/wp-content/uploads/ri_rare_plants_2007.pdf one extant population NH S2 threatened New Hampshire Natural Heritage Inventory. 2011. Rare plant list for New Hampshire Concord, NH: New Hampshire Heritage Bureau, Division of Forests and Lands. Accessed online at http://www.nhdfl.org/library/pdf/Natural%20Heritage/TrackingList- PlantGeneral.pdf NC special concern Plant Industry -Plant Conservation ( 2011) Ginseng Raleigh, NS: North Carolina Department of Agriculture and Consumer Services. Accessed at http://www.ncagr.gov/plantindustry/plant/plantconserve/ginseng.htm MA special concern Natural Heritage and Endangered Species Program. 2008. Massachusetts list of endangered, threatened, and special concern species. Westborough, MA: Massachusetts Division of Fisheries and Wildlife accessed at http://www.mass.gov/dfwele/dfw/nhesp/species_info/mesa_list/mesa_list.htm PA vulnerable Thompson, S.A. 1997 (20 October 2002). Department of Conservation and Natural Resources, Pennsylvania.
PA DNR. (2011) Vulnerable plants in Pennsylvania. Accessed at http://www.dcnr.state.pa.us/forestry/wildplant/vulnerable_plants.aspx TN commercially exploited S-CE S3S4 Tennessee Natural Heritage Program. 2008. Rare plant list Nashville, Tennessee: Department of Environment and Conservation, Division of Natural Areas. Accessed at http://www.state.tn.us/environment/na/pdf/plant_list.pdf.